Biostem Technologies Inc
OTC:BSEM

Watchlist Manager
Biostem Technologies Inc Logo
Biostem Technologies Inc
OTC:BSEM
Watchlist
Price: 13.28 USD -1.99%
Market Cap: 217m USD
Have any thoughts about
Biostem Technologies Inc?
Write Note

Biostem Technologies Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biostem Technologies Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Biostem Technologies Inc
OTC:BSEM
Total Receivables
$11.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Receivables
$16.2B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Total Receivables
$14.9B
CAGR 3-Years
8%
CAGR 5-Years
23%
CAGR 10-Years
17%
Pfizer Inc
NYSE:PFE
Total Receivables
$15.1B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
4%
Merck & Co Inc
NYSE:MRK
Total Receivables
$12.2B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Total Receivables
$12.1B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
13%
No Stocks Found

Biostem Technologies Inc
Glance View

Market Cap
217m USD
Industry
Pharmaceuticals

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.

BSEM Intrinsic Value
18.02 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Biostem Technologies Inc's Total Receivables?
Total Receivables
11.4m USD

Based on the financial report for Dec 31, 2023, Biostem Technologies Inc's Total Receivables amounts to 11.4m USD.

What is Biostem Technologies Inc's Total Receivables growth rate?
Total Receivables CAGR 1Y
3 691%

Over the last year, the Total Receivables growth was 3 691%.

Back to Top